img 614-636-4850
  • Follow us:


KEY ADVISORS



Biosortia is on the cutting edge of natural products discovery. It’s Scientific Team and Advisors have the experience and know-how to decipher this complex unexplored environment in a very efficient manner to bring thousands of novel natural product compounds to market at a time where there is a critical need for new drugs to combat Cancer, CNS, Inflammation, and Infectious Disease. Biosortia has established deep relationships with best in class advisors. Each relationship is uniquely selected based upon its ability to accelerate Biosortia’s aspiration of becoming the premier, aquatic natural products discovery company. Biosortia’s advisory team is multi-disciplinary bringing the full range of operational leadership experience across the critical disciplines – science, technology, product development and senior leadership within the pharmaceutical manufacturing industry. Each Advisor is actively involved providing Biosortia with perspective, expertise and counsel from years of executive experience at successful companies. In addition, they provide critical access to established relationships and extensive networks throughout the life sciences, industry, and academic communities. Our relationships provide deep knowledge of discovering and advancing the unique, novel, and rare compounds and fractions through the drug discovery and development process.


Tim Wright - Timothy R. Wright was appointed Executive Vice President, Business Development, Strategy and Innovation, for Teva Pharmaceutical Industries Ltd. in April 2015. Mr. Wright currently serves as Founder and Chairman of the Drug Discovery and Development Institute for The Ohio State University Comprehensive Cancer Center. He has previously served as President of Covidien Pharmaceuticals from 2007-2010. He was CEO (Interim) & President, BOD and Chief Operating Officer from 2004-2007 at AAI. He was CEO (Interim) & President, a member of the board of directors and Chief Operating Officer at AAI Pharmaceu- ticals/Xanodyne from 2004-2007. He served at Elan Bio-Pharmaceuticals as President, Global Operations from 2001-2004 and President, Europe, Japan & ROW and Executive Vice President, Business Development & Licensing from 2001-2002. During 1984-1999, he served at DuPont Merck Pharmaceutical Company, holding roles such as Senior Vice President, Strategy & Corporate Business Development from 1996-1999, Vice President, Strategic Marketing & Operations – Europe from 1995-1996, President & CEO, Toronto, Canada from 1993-1995, and Vice President, Marketing from 1990-1993. Mr. Wright holds a B.Sc. from The Ohio State University. Mr. Wright brings to the organization a wealth of knowledge and experience specifically in the pharmaceuticals manufacturing space and related impacts on drug discovery.


Richard Trauger Ph.D., Chairman of Scientific Advisory Board - Dr. Trauger is a Cell biologist/Virologist with extensive experience in pre-clinical and clinical development of therapeutics for oncology and infectious disease. Most recently (2013 – 2017) as a R&D consultant and then Director of Virology for Ansun Biopharma, Richard managed clinical virology activities for Influenza and Parainfluenza programs in Phase 2 clinical trials. Before that in 2012, CytoDyn Inc appointed Richard Trauger to serve as the Company's Chief Scientific Officer. He was appointed as a director on October 10, 2012. Dr. Trauger previously served as the Company's Managing Director of Science beginning in January 2011. He is responsible for all aspects of the Company's Research and Development programs including the design and execution of all scientific research. Dr. Trauger has over 20 years of experience in the HIV/AIDS space. From July 15, 2009 through January 1, 2011, Dr. Trauger was a consultant for Search For A Cure and ICBI, specializing in activities directed towards the commercialization of monoclonal antibodies for the treatment of disease. Dr. Trauger was the Senior Director of Infectious Disease and Cancer for Hollis-Eden Pharmaceuticals, Inc. ("Hollis-Eden") from August 26, 2001 through July 1, 2008, where his primary focus in infectious disease was HIV, influenza and malaria. His primary focus in cancer was prostate and breast cancer. Dr. Trauger also served as project leader for Hollis Eden's lead cancer compound for the treatment of prostate and breast cancer, Hollis Eden's scientific liaison to the business development group, and project leader for the trauma program. Dr. Trauger received his Ph.D. from the University of South Carolina School of Medicine in 1986 in biomedical science, specializing in retrovirology. Dr. Trauger brings his extensive medical background and expertise to the Board. Dr. Trauger also brings a unique insight as a result of his scientific understanding and research abilities.


Peter Moeller, Ph.D. - Dr. Moeller, NOAA Research Scientist, leads the Toxins Natural Products Program at Hollings Marine Laboratory and is a faculty member at Medical University of South Carolina. Dr. Moeller is an internationally recognized authority in aquatic natural products chemistry. He brings over 30 years of experience and has been involved with Biosortia since 2010. He provides daily counsel to our research team imbedded at NOAA in South Carolina. Through our CRADA (Cooperative Research and Development Agreement) with NOAA, Dr. Moeller is a key member of our team providing expert experience in defining our harvesting strategy to ensure a continual stream of unique compounds.


Paul V. Zimba, Ph.D. - Dr. Zimba is Director of the Texas A&M Corpus Christi Center for Coastal Studies. He is an internationally renowned expert in aquatic culturing and biology He is an adjunct at the University of Mississippi and the State University of New York SUNY and has also served as an Adjunct Faculty member at Loyola University of New Orleans. His research interests include aquatic ecosystem ecology algal toxin assessment harmful algae wetlands aquaculture microalgal taxonomy and physiology carbon fixation assessment remote sensing aquatic ecosystem stressors and cyanobacteria secondary metabolites. Dr. Zimba earned his BA in Biological Sciences at Virginia Wesleyan College, Masters in Biology from Old Dominion University and PhD from Mississippi State University. Dr. Zimba has presented at the Gordon Conference on Mycotoxins and Phycotoxins and served on the editorial board of two international journals as well as the Board of Trustees of the Phycological Society of America.